Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION • Market outline PART 05: DISEASE OVERVIEW PART 06: MARKET ECOSYSTEM • Market segmentation analysis PART 07: MARKET SIZING • Market size and forecast 2016-2021 PART 08: PIPELINE ANALYSIS PART 09: FIVE FORCES ANALYSIS PART 10: MARKET SEGMENTATION BY PRODUCT TYPE • Segmentation by product type • Comparison by product type • Global pneumonia vaccines market • Global pneumonia anti-infectives market • Global pneumonia oxygen therapy market • Market opportunity by product type PART 11: MARKET SEGMENTATION BY PNEUMONIA TYPE • CAP • HCAP PART 12: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Pneumonia therapeutics market in Americas • Pneumonia therapeutics market in EMEA • Pneumonia therapeutics market in APAC • Market opportunity PART 13: DECISION FRAMEWORK PART 14: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 15: MARKET TRENDS • Strong pipeline • Rising global initiatives for pneumonia treatment • Rise in respiratory infection cases PART 16: VENDOR LANDSCAPE PART 17: VENDOR ANALYSIS • Vendor overview • GlaxoSmithKline • Merck Sharp & Dohme • Novartis • Pfizer PART 18: APPENDIX • List of abbreviations List of Exhibits Exhibit 01: Global pneumonia therapeutics categories Exhibit 02: Parent market of the global pneumonia therapeutics market Exhibit 03: Global pneumonia therapeutics market segments Exhibit 04: Global pneumonia therapeutics market 2016-2021 ($ millions) Exhibit 05: Global pneumonia therapeutics market year-over-year (YoY) growth 2017-2021 (%) Exhibit 06: Global pneumonia therapeutics pipeline landscape Exhibit 07: Key clinical trials in the global pneumonia therapeutics market Exhibit 08: Global pneumonia therapeutics market by product type 2016-2021 (%) Exhibit 09: Global pneumonia therapeutics market comparison by product type Exhibit 10: Global pneumonia vaccines market 2016-2021 ($ millions) Exhibit 11: Global pneumonia vaccines market YoY growth 2017-2021 (%) Exhibit 12: Global pneumonia anti-infectives market 2016-2021 ($ millions) Exhibit 13: Global pneumonia anti-infectives market YoY growth 2017-2021 (%) Exhibit 14: Global pneumonia oxygen therapy market 2016-2021 ($ millions) Exhibit 15: Global pneumonia oxygen therapy market YoY growth 2017-2021 (%) Exhibit 16: Market opportunity by product type Exhibit 17: Global pneumonia therapeutics market by geography 2016-2021 (%) Exhibit 18: Regional comparison Exhibit 19: Pneumonia therapeutics market in Americas 2016-2021 ($ millions) Exhibit 20: Pneumonia therapeutics market YoY growth in Americas 2017-2021 (%) Exhibit 21: Pneumonia therapeutics market in EMEA 2016-2021 ($ millions) Exhibit 22: Pneumonia therapeutics market YoY growth in EMEA 2017-2021 (%) Exhibit 23: Pneumonia therapeutics market in APAC 2016-2021 ($ millions) Exhibit 24: Pneumonia therapeutics market YoY growth in APAC 2017-2021 (%) Exhibit 25: Factors driving awareness toward prophylaxis treatment Exhibit 26: Development of microbial resistance Exhibit 27: Major global initiatives for pneumonia treatment Exhibit 28: GlaxoSmithKline: Key highlights Exhibit 29: GlaxoSmithKline: Strength assessment Exhibit 30: GlaxoSmithKline: Strategy assessment Exhibit 31: GlaxoSmithKline: Opportunity assessment Exhibit 32: Merck Sharp & Dohme: Key highlights Exhibit 33: Merck Sharp & Dohme: Strength assessment Exhibit 34: Merck Sharp & Dohme: Strategy assessment Exhibit 35: Merck Sharp & Dohme: Opportunity assessment Exhibit 36: Novartis: Key highlights Exhibit 37: Novartis: Strength assessment Exhibit 38: Novartis: Strategy assessment Exhibit 39: Novartis: Opportunity assessment Exhibit 40: Pfizer: Key highlights Exhibit 41: Pfizer: Strength assessment Exhibit 42: Pfizer: Strategy assessment Exhibit 43: Pfizer: Opportunity assessment

GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pfizer, AstraZeneca, Bayer, Biotest, Ono Pharmaceutical, and Tetraphase Pharmaceuticals.